Taysha Gene Therapies Inc (TSHA)
Healthcare
Biotechnology
—
5.90 $
-0.3%
vs. previous close
Closing price · As of: 31. Jul 2026
Taysha Gene Therapies Inc (TSHA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -93 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| 0.1 | -31 | -117 | -88 | -73 | -81 | -93 | |
| 0.0 | 0.0 | 0.5 | 1.2 | 1.4 | 1.2 | 1.1 | |
| – | 3.4 | 18 | 18 | 7.9 | 13 | 13 | |
| 3.9 | 29 | 28 | 58 | – | – | – | |
| 0.5 | -0.1 | 29 | 19 | -18 | -12 | -5.4 | |
| 0.1 | 9.1 | 22 | 25 | 7.4 | 0.4 | 0.7 | |
| -9.1 | -9.1 | -22 | -25 | -7.4 | -0.4 | -0.6 | |
| – | 291 | – | – | – | – | – | |
| 40 | 40 | 40 | 0.0 | -3.5 | 0.0 | 9.2 | |
| 291 | 291 | 39 | 52 | 136 | 77 | 275 | |
| 0.1 | 251 | -100 | -61 | 56 | -4.9 | 181 | |
| 0.1 | -40 | -139 | -113 | -80 | -82 | -94 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.